Translational research is the critical bridge between basic research and clinical research – the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment and prevention of human disease. Unfortunately, much promising research falls into a "valley of death" of funding and management, between basic discovery - largely funded by the government - and later-stage clinical research - usually funded by industry. What can be done to bridge this gap and rescue good ideas? How can we draw those standing on each side of the Valley closer together?
Moderator:
Sharon Begley, Science Editor, Newsweek
Speakers:
Robi Blumenstein, President, CHDI Management/CHDI Foundation
Randall Carpenter, Co-Founder, President and Chief Executive Officer, Seaside Therapeutics
Christian Loucq, Director, PATH Malaria Vaccine Initiative
Dennis Purcell, Aisling Capital
Dennis Purcell, Managing Partner, Aisling Capital
Amy Comstock Rick, Chief Executive Officer, Parkinson's Action Network
Back to Program Schedule and Sessions |
